Litcius/Paper detail

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

Anna‐Lena Volckmar, Petros Christopoulos, Martina Kirchner, Michael Allgäuer, Olaf Neumann, Jan Budczies, Eugen Rempel, Peter Horak, Julia Glade, Hannah Goldschmid, Huriye Seker‐Cin, Regine Brandt, Mark Kriegsmann, Jonas Leichsenring, H. Winter, Martin Faehling, Jürgen R. Fischer, Claus Peter Heußel, Felix Herth, Tilman Brummer, Stefan Fröhling, Peter Schirmacher, Michael Thomas, Volker Endris, Roland Penzel, Daniel Kazdal, Tilmann Bochtler, Albrecht Stenzinger

2021Lung Cancer17 citationsDOI

Topics & Concepts

MedicineROS1OncologyTargeted therapyLung cancerInternal medicineClinical trialnon-small cell lung cancer (NSCLC)Personalized medicineCancer researchCancerBioinformaticsAdenocarcinomaBiologyA549 cellLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentMelanoma and MAPK Pathways
Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field | Litcius